- Home
- NGNE vs RMM Comparison
NGNE vs RMM Comparison
Compare NGNE & RMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- RMM
- Stock Information
- Founded
- NGNE 2003
- RMM 2019
- Country
- NGNE United States
- RMM United States
- Employees
- NGNE N/A
- RMM N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- RMM Trusts Except Educational Religious and Charitable
- Sector
- NGNE Health Care
- RMM Finance
- Exchange
- NGNE Nasdaq
- RMM Nasdaq
- Market Cap
- NGNE 325.3M
- RMM 265.5M
- IPO Year
- NGNE N/A
- RMM N/A
- Fundamental
- Price
- NGNE $19.95
- RMM $13.61
- Analyst Decision
- NGNE Strong Buy
- RMM
- Analyst Count
- NGNE 7
- RMM 0
- Target Price
- NGNE $41.86
- RMM N/A
- AVG Volume (30 Days)
- NGNE 113.3K
- RMM 66.5K
- Earning Date
- NGNE 08-11-2025
- RMM 01-01-0001
- Dividend Yield
- NGNE N/A
- RMM 7.33%
- EPS Growth
- NGNE N/A
- RMM N/A
- EPS
- NGNE N/A
- RMM 0.96
- Revenue
- NGNE N/A
- RMM N/A
- Revenue This Year
- NGNE N/A
- RMM N/A
- Revenue Next Year
- NGNE N/A
- RMM N/A
- P/E Ratio
- NGNE N/A
- RMM $15.55
- Revenue Growth
- NGNE N/A
- RMM N/A
- 52 Week Low
- NGNE $6.88
- RMM $12.32
- 52 Week High
- NGNE $74.49
- RMM $16.10
- Technical
- Relative Strength Index (RSI)
- NGNE 48.86
- RMM 53.29
- Support Level
- NGNE $18.00
- RMM $13.37
- Resistance Level
- NGNE $19.93
- RMM $13.70
- Average True Range (ATR)
- NGNE 1.03
- RMM 0.12
- MACD
- NGNE 0.01
- RMM 0.01
- Stochastic Oscillator
- NGNE 55.71
- RMM 56.80
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.